Gilgamesh Pharmaceuticals Inc. has identified phenalkylamine compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric disorders.
Astrogen Co. Ltd. has synthesized prodrugs of 4-hydroxy atomoxetine reported to be useful for the treatment of aphasia, apraxia, attention deficit hyperactivity disorder, cognitive disorders, Alzheimer’s disease, Parkinson’s disease and ischemic stroke.
Shenzhen Zhongge Biotechnology Co. Ltd. has described tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Yeda Research and Development Co. Ltd. has divulged broad-spectrum coronavirus entry inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19), SARS-CoV infection and Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
University College Cardiff Consultants Ltd. has identified miglustat prodrugs reported to be useful for the treatment of lysosomal storage diseases, Down syndrome and neurodegenerative disorders.
Researchers from China Pharmaceutical University and Jiangsu Nhwa Pharmaceutical Co. Ltd. have synthesized azetidine-containing compounds acting as muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, asthma, pain, schizophrenia, pulmonary hypertension, Huntington’s disease, Parkinson’s disease and sleep disorders among others.
Erasmus Universitair Medisch Centrum Rotterdam has disclosed drug conjugates consisting of a 1,3,5-triazine core or a 1,3,5-triazinane core that is connected to two FAP-binding moieties via linkers and to a payload via another linker reported to be useful for the diagnosis and treatment of cancer.
Scientists at Zai Lab (Shanghai) Co. Ltd. and Zai Lab (US) LLC have described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
RSS